HLB Life Science Co. Ltd (067630) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HLB Life Science Co. Ltd (067630) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.30 Billion ≈ $-2.92 Million USD) by net assets (₩277.26 Billion ≈ $187.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 067630 company net worth for the company's overall valuation and market capitalisation.
HLB Life Science Co. Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how HLB Life Science Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
HLB Life Science Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HLB Life Science Co. Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of HLB Life Science Co. Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GAM Holding AG
SW:GAM
|
-2.427x |
|
North European Oil Royalty Trust
NYSE:NRT
|
1.270x |
|
NAU IB Capital
KQ:293580
|
-0.026x |
|
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS
IS:KATMR
|
-0.038x |
|
BaoMinh Insurance Corp
VN:BMI
|
0.005x |
|
KCTC Co. Ltd
KO:009070
|
0.034x |
|
Hyundai Everdigm Corp
KQ:041440
|
-0.014x |
|
iFabric Corp
TO:IFA
|
-0.083x |
Annual Cash Flow Conversion Efficiency for HLB Life Science Co. Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of HLB Life Science Co. Ltd from 2012 to 2024. View HLB Life Science Co. Ltd (067630) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩398.83 Billion ≈ $270.28 Million |
₩-32.01 Billion ≈ $-21.69 Million |
-0.080x | -85.25% |
| 2023-12-31 | ₩231.21 Billion ≈ $156.69 Million |
₩-10.02 Billion ≈ $-6.79 Million |
-0.043x | +65.81% |
| 2022-12-31 | ₩234.72 Billion ≈ $159.07 Million |
₩-29.74 Billion ≈ $-20.16 Million |
-0.127x | -121.50% |
| 2021-12-31 | ₩246.19 Billion ≈ $166.84 Million |
₩-14.08 Billion ≈ $-9.54 Million |
-0.057x | -917.36% |
| 2020-12-31 | ₩287.18 Billion ≈ $194.62 Million |
₩2.01 Billion ≈ $1.36 Million |
0.007x | +118.86% |
| 2019-12-31 | ₩333.82 Billion ≈ $226.23 Million |
₩-12.39 Billion ≈ $-8.39 Million |
-0.037x | +26.58% |
| 2018-12-31 | ₩219.09 Billion ≈ $148.47 Million |
₩-11.07 Billion ≈ $-7.50 Million |
-0.051x | -783.95% |
| 2017-12-31 | ₩52.83 Billion ≈ $35.80 Million |
₩-302.04 Million ≈ $-204.69K |
-0.006x | +93.04% |
| 2016-12-31 | ₩27.68 Billion ≈ $18.76 Million |
₩-2.27 Billion ≈ $-1.54 Million |
-0.082x | +51.02% |
| 2015-12-31 | ₩25.90 Billion ≈ $17.55 Million |
₩-4.34 Billion ≈ $-2.94 Million |
-0.168x | -121.60% |
| 2014-12-31 | ₩13.44 Billion ≈ $9.11 Million |
₩10.43 Billion ≈ $7.07 Million |
0.776x | +190.44% |
| 2013-12-31 | ₩11.03 Billion ≈ $7.48 Million |
₩2.95 Billion ≈ $2.00 Million |
0.267x | -86.53% |
| 2012-12-31 | ₩7.04 Billion ≈ $4.77 Million |
₩13.97 Billion ≈ $9.47 Million |
1.984x | -- |
About HLB Life Science Co. Ltd
HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendoc… Read more